GlassScriptPhysician profile
Laura B Buford
NPI 1861803058
$6,054.74
in general payments reported to CMS, 2019-2025
30 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $257 · 2021: $442 · 2022: $338 · 2023: $1,754 · 2024: $1,285 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,942 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,941.68 |
| Education | $169.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,045.87 | 2019-2025 | Skyrizi, Rinvoq |
| Galderma Laboratories, L.P. | $653.72 | 2019-2025 | Aklief, Oracea, Epsolay |
| Sun Pharmaceutical Industries INC. | $518.05 | 2019-2025 | Absorica Ld, Winlevi |
| Ucb, INC. | $453.13 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $402.06 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $271.78 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $241.18 | 2019-2025 | |
| Genzyme Corporation | $234.75 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $233.67 | 2019-2025 | Dupixent, Libtayo |
| Almirall LLC | $228.60 | 2019-2025 | Seysara |
| Merz North America, INC. | $226.48 | 2019-2023 | |
| Pfizer INC. | $187.65 | 2019-2024 | |
| Revance Therapeutics, INC. | $171.89 | 2025 | Daxi, Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $147.61 | 2019-2025 | Cabtreo, Jublia, Duobrii |
| Leo Pharma INC. | $136.94 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $129.67 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $117.62 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $89.95 | 2024 | |
| Dermavant Sciences, INC. | $88.36 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $81.74 | 2023-2024 | Zoryve |
| Biofrontera INC. | $75.13 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Lilly USA, LLC | $72.39 | 2019-2024 | Olumiant, Taltz |
| Incyte Corporation | $56.71 | 2022-2025 | Opzelura |
| Epi Health, LLC | $48.54 | 2021-2022 | |
| Journey Medical Corporation | $35.24 | 2022-2023 | |
| Vyne Pharmaceuticals INC. | $34.51 | 2021 | |
| Amgen INC. | $28.50 | 2024 | Otezla |
| Axsome Therapeutics, INC. | $17.67 | 2025 | Auvelity |
| Prugen, INC. Pharmaceuticals | $13.53 | 2019 | |
| Strata Skin Sciences, INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Buford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.